dc.contributor.author | Frischmuth, Tobias | |
dc.contributor.author | Hindberg, Kristian | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Brækkan, Sigrid Kufaas | |
dc.contributor.author | Hansen, John Bjarne | |
dc.contributor.author | Morelli, Vania Maris | |
dc.date.accessioned | 2022-09-13T09:17:46Z | |
dc.date.available | 2022-09-13T09:17:46Z | |
dc.date.issued | 2022-03-15 | |
dc.description.abstract | Background: Plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous
thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated
with VTE remains uncertain.<p>
<p>Objective: To investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity.
Methods: A population-based nested case-control study, comprising 383 VTE cases
and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort.
PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic
regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs)
for VTE across PAI-1 tertiles.
<p>Results: The VTE risk increased dose-dependently across PAI-1 tertiles (P for trend
<.001) in the age- and sex-adjusted model. The OR of VTE for the highest versus lowest tertile was 1.73 (95% CI 1.27–2.35), and risk estimates were only slightly attenuated with additional stepwise adjustment for body mass index (BMI; OR 1.59, 95% CI
1.16–2.17) and C-reactive protein (CRP; OR 1.54, 95% CI 1.13–2.11). Similar results
were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. In obese subjects (BMI of ≥30 kg/m<sup>2</sup>
vs. <25 kg/m<sup>2</sup>
), PAI-1 mediated
14.9% (95% CI 4.1%-49.4%) of the VTE risk in analysis adjusted for age, sex, and CRP.
<p>Conclusion: Our findings indicate that plasma PAI-1 is associated with increased risk of
future incident VTE and has the potential to partially mediate the VTE risk in obesity. | en_US |
dc.identifier.citation | Frischmuth, Hindberg, Aukrust, Ueland, Brækkan, Hansen, Morelli. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. Journal of Thrombosis and Haemostasis. 2022 Jul;20(7):1618-1626 | en_US |
dc.identifier.cristinID | FRIDAID 2019108 | |
dc.identifier.doi | 10.1111/jth.15701 | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.issn | 1538-7836 | |
dc.identifier.uri | https://hdl.handle.net/10037/26780 | |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Frischmuth, T. (2023). Obesity-related venous thromboembolism. (Doctoral thesis). <a href=https://hdl.handle.net/10037/28520>https://hdl.handle.net/10037/28520</a>. | |
dc.relation.journal | Journal of Thrombosis and Haemostasis | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.title | Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |